- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/075 - Adénoviridae
Détention brevets de la classe C07K 14/075
Brevets de cette classe: 349
Historique des publications depuis 10 ans
9
|
22
|
31
|
23
|
23
|
34
|
33
|
42
|
22
|
12
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
Proprétaire |
Total
|
Cette classe
|
---|---|---|
The Regents of the University of California | 19887 |
16 |
The University of North Carolina at Chapel Hill | 2030 |
14 |
The Trustees of the University of Pennsylvania | 4317 |
12 |
Glaxosmithkline Biologicals S.A. | 1637 |
11 |
University of Massachusetts | 2224 |
11 |
The Salk Institute for Biological Studies | 445 |
9 |
Children's Medical Research Institute | 65 |
7 |
Janssen Vaccines & Prevention B.V. | 295 |
6 |
Joint Stock Company "BIOCAD" | 184 |
6 |
University of Washington through its Center for Commercialization | 507 |
6 |
The Board of Trustees of the Leland Stanford Junior University | 6403 |
5 |
University of Florida Research Foundation, Inc. | 4016 |
5 |
Institut Catala D'oncologia (ico) | 14 |
5 |
The Broad Institute, Inc. | 1800 |
4 |
Children's National Medical Center | 271 |
4 |
Fundacio Institut D'investigacio Biomedica de Bellvitge (idibell) | 67 |
4 |
GenVec, Inc. | 58 |
4 |
University of Washington | 2322 |
4 |
Angiocrine BioScience, Inc. | 37 |
4 |
Forge Biologics, Inc. | 16 |
4 |
Autres propriétaires | 208 |